Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Abivax S.A.NASDAQ: ABVX

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income remains negative

Q2 FY2026 operating income was -€84.11M, compared with -€46.5M a year earlier.

Context

  • Operating income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 10 analysts of €0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -42.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-€84.11M— QoQ
Last fiscal yearDec 2025
-€246.06M-42.2% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.9%——
1 year-42.2%+100.0%+142.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

EUR · from the income statement

Latest · FY2025
(246.06M) EUR
Year-over-year change
-42.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -42.2% is the 8th highest of 11, against a peer median of -14.6%.
ABVX Competitors
Operating Income for ABVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$289.66M USD+208.4%—41.3%
ANABAnaptysBio, Inc.LTM Mar 2026$40.8M USD+140.7%—17.6%
IMMXImmix Biopharma, Inc.LTM Mar 2026-$36.08M USD-65.8%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$79.16M USD-57.0%—134164.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$80.48M USD+43.0%—961.9%
IVAInventiva S.A.FY2025-€130.95M EUR-34.2%—2921.0%
ANNXAnnexon, Inc.LTM Mar 2026-$205.06M USD-12.1%——
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-$223.53M USD+35.0%—102.9%
ABVXAbivax S.A.FY2025-€246.06M EUR-42.2%——
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$250.17M USD-17.1%—276.5%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$486M USD-43.8%—415.4%
Peer median (excluding ABVX) —-14.6%—345.9%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue45.52M50.76M000
Gross Profit(45.52M)(50.76M)000
Gross Margin—————
Research & Development47.78M48.3M103.18M146.53M177.76M
Selling, General & Admin5.58M7.49M28.82M38.9M72.87M
Operating Expenses(4.12M)14.07M127.38M172.98M246.06M
Depreciation & Amortization302K485K707K1.1M1.07M
EBITDA(38.59M)(53.32M)(133.21M)(162.71M)(300.7M)
EBITDA Margin—————
Operating Income(41.4M)(64.84M)(127.38M)(172.98M)(246.06M)
Operating Margin—————
Interest Income002.77M8.96M5.75M
Interest Expense3.56M6.94M13.83M12.43M28.48M
Other Income / Expenses(1.05M)4.1M(20.36M)(3.26M)(84.2M)
Income Before Tax(42.45M)(60.74M)(147.74M)(176.24M)(330.25M)
Pre-Tax Margin—————
Income Tax Expense00005.85M
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(336.1M)
Net Margin—————
EPS (Basic)(2.75)(3.18)(3.43)(2.80)(4.65)
EPS (Diluted)(2.75)(3.18)(3.43)(2.80)(4.65)
Weighted Avg Shares15.46M19.09M43.07M63.05M69.53M
Weighted Avg Shares (Diluted)15.46M19.09M43.07M63.05M69.53M

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.